Shield Therapeutics PLC | Income Statement
Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
304.00
637.00
11,881
Cost of Goods Sold (COGS) incl. D&A
32.00
36.00
50.00
2,036.00
2,592.00
2,665
Gross Income
32.00
36.00
50.00
1,732.00
1,955.00
9,216
SG&A Expense
4,054.00
3,599.00
6,605.00
10,601.00
18,996.00
14,384
EBIT
4,086.00
3,635.00
6,655.00
12,333.00
20,951.00
5,168
Unusual Expense
569.00
8,585.00
18,123.00
2,565.00
-
-
Non Operating Income/Expense
266.00
450.00
2,162.00
749.00
41.00
30
Interest Expense
1,266.00
1,660.00
1,872.00
14.00
17.00
35
Pretax Income
4,517.00
13,430.00
24,488.00
15,603.00
20,994.00
5,153
Income Tax
-
-
-
587.00
1,406.00
3,359
Consolidated Net Income
4,517.00
13,430.00
24,488.00
15,016.00
19,588.00
1,794
Net Income
4,189.00
12,905.00
23,627.00
15,016.00
19,588.00
1,794
Net Income After Extraordinaries
4,189.00
12,905.00
23,627.00
15,016.00
19,588.00
1,794
Net Income Available to Common
4,189.00
12,905.00
23,627.00
15,016.00
19,588.00
1,794
EPS (Basic)
0.04
0.12
0.22
0.15
0.17
0.02
Basic Shares Outstanding
108,135.40
108,135.40
108,135.40
101,160.00
112,358.00
116,426
EPS (Diluted)
0.04
0.12
0.22
0.15
0.17
0.02
Diluted Shares Outstanding
108,135.40
108,135.40
108,135.40
101,160.00
112,358.00
116,426
EBITDA
4,054.00
3,599.00
6,605.00
10,397.00
18,514.00
2,814
Non-Operating Interest Income
-
-
-
58.00
15.00
20
Minority Interest Expense
328.00
525.00
861.00
-
-
-
About Shield Therapeutics
View Profile
